A new publication examining bremelanotide was released on May 22, 2026. The paper, titled "Clinical trial evidence on emerging pharmacological therapies for hypoactive sexual desire disorder in women: a systematic review and analysis of completed studies registered on ClinicalTrials.gov," appeared in Frontiers in Medicine.
The publication is described as a systematic review and analysis of completed studies registered on ClinicalTrials.gov. It focuses on emerging pharmacological therapies for hypoactive sexual desire disorder, or HSDD, in women.
No specific findings, outcomes, or conclusions from the review have been detailed in the available event data. The scope of the publication is limited to a review and analysis of trial evidence already registered on ClinicalTrials.gov for this therapeutic area.
Bremelanotide remains an approved compound. This publication represents a new addition to the academic literature examining pharmacological approaches to HSDD, of which bremelanotide is one subject.
Readers interested in additional background on this compound can consult the compound overview for further context.